A Comparative Analysis of Testosterone Therapy and Phosphodiesterase 5 Inhibitor Monotherapy and Combined Therapy in Men with Erectile Dysfunction and Low Testosterone Levels

2020 ◽  
Vol 40 (1) ◽  
pp. 11
Author(s):  
David Julien ◽  
Loralee Sessanna ◽  
Nancy Campbell
Keyword(s):  
Erectile Dysfunction ◽  
Comparative Analysis ◽  
Combined Therapy ◽  
Testosterone Therapy ◽  
Phosphodiesterase 5 Inhibitor ◽  
Testosterone Levels ◽  
Low Testosterone ◽  
Phosphodiesterase 5

021 Cessation of Phosphodiesterase 5 Inhibitor Use in Men with Erectile Dysfunction Following Testosterone Therapy

2017 ◽  
Vol 14 (2) ◽  
pp. e10
Author(s):  
J.S. Lin ◽  
A.W. Pastuszak ◽  
S.J. Ohlander ◽  
T.S. Hakky ◽  
D.J. Lamb ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Testosterone Therapy ◽  
Phosphodiesterase 5 Inhibitor ◽  
Phosphodiesterase 5

Efficacy of Tadalafil in Men with Erectile Dysfunction Naïve to Phosphodiesterase 5 Inhibitor Therapy Compared with Prior Responders to Sildenafil Citrate

2006 ◽  
Vol 3 (4) ◽  
pp. 668-675 ◽  
Author(s):  
Gregory A. Broderick ◽  
Craig F. Donatucci ◽  
Dimitrios Hatzichristou ◽  
Luiz O. Torres ◽  
Luc Valiquette ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Inhibitor Therapy ◽  
Sildenafil Citrate ◽  
Phosphodiesterase 5 Inhibitor ◽  
Phosphodiesterase 5

Metabolic Syndrome in Men with Low Testosterone Levels: Relationship with Cardiovascular Risk Factors and Comorbidities and with Erectile Dysfunction

2013 ◽  
Vol 10 (10) ◽  
pp. 2529-2538 ◽  
Author(s):  
Eduardo García‐Cruz ◽  
Asier Leibar‐Tamayo ◽  
Javier Romero ◽  
Marta Piqueras ◽  
Pilar Luque ◽  
...  
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Erectile Dysfunction ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Testosterone Levels ◽  
Low Testosterone
Sign in / Sign up

Export Citation Format

Share Document